Clinical trial
Endostatin in Treating Patients With Advanced Solid Tumors
NCT00004229 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004229 |
|---|---|
| Title | Endostatin in Treating Patients With Advanced Solid Tumors |
| Official title | A Phase I Surrogate Endpoint Trial of Human Recombinant Endostatin in Patients With Advanced Solid Tumors Amenable to Biopsy |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Biological |
| Interventions | recombinant human endostatin |
| Enrollment | 30 |
| Start date | Oct 1, 1999 |
| Primary completion | Oct 1, 2002 |
| First posted | Apr 19, 2004 |
| Last update posted | Feb 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: